AL
TGTX icon

Airain Ltd’s TG Therapeutics TGTX Stock Holding History

Airain Ltd’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-12,313
Closed -$147K – 1060
2015
Q4 		$147K Buy
+12,313
New +$156K 0.01% 748
2015
Q3 		– Sell
-25,353
Closed -$421K – 1058
2015
Q2 		$421K Buy
+25,353
New +$401K 0.02% 560

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Airain Ltd's TGTX Position: Q1 2016 in Review

Airain Ltd sold out of TG Therapeutics (TGTX) in Q1 2016, closing a stake of 12,313 shares — an estimated $147K sold.

Airain Ltd first reported a position in TGTX in Q2 2015 and held it in 2 quarters. The position peaked at $421K in Q2 2015. 81 funds tracked by Wall St. Rank hold TGTX as of Q1 2016.

  • Airain Ltd reported no remaining TG Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Airain Ltd sold 12,313 TG Therapeutics shares in Q1 2016, an estimated $147K.
  • Airain Ltd first reported a position in TG Therapeutics in Q2 2015 and held it in 2 quarters.
  • Airain Ltd's TG Therapeutics position peaked at $421K in Q2 2015.
  • 81 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.